^
Association details:
| Biomarker: | PRAME expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | IMC-F106C (CD3 agonist, PRAME inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 5572: IMC-F106C, a novel and potent immunotherapy approach to treat PRAME expressing solid and hematologic tumors
Published date:
05/15/2020
Excerpt:
In the PRAME positive HLA-A*02:01 positive cell lines, IMC-F106C redirected donor effector cells to release IFNγ and GrB and kill tumor cells in a dose-dependent manner, with activity demonstrated as low as < 1 pM. By contrast, cell lines negative for PRAME or HLA-A*02:01 expression failed to induce responses < 1 nM of IMC-F106C.
DOI:
10.1158/1538-7445.AM2020-5572
